ICAD Antibody (B-6): sc-17818
- ICAD Antibody (B-6) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 1-331 representing full length ICAD of human origin
- recommended for detection of ICAD of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP, m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for ICAD Antibody (B-6) for WB applications. These reagents are now offered in bundles with ICAD Antibody (B-6) (see ordering information below).
QUICK LINKS
ICAD Antibody (B-6) is a mouse monoclonal IgG2b light chain antibody that detects ICAD in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ICAD, or Inhibitor of Caspase-Activated DNase, plays a crucial role in the regulation of apoptosis by inhibiting the activity of caspase-activated DNase, which is essential for DNA fragmentation during programmed cell death. This function is vital as ICAD helps maintain genomic integrity and prevents unwanted cell death, which can lead to various diseases, including cancer. The interaction between ICAD and caspase-activated DNase is a key regulatory mechanism that ensures apoptosis occurs in a controlled manner, allowing for the proper removal of damaged or unnecessary cells while preserving healthy tissue. Anti-ICAD antibody (B-6) provides reliable detection of ICAD, facilitating research into ICAD′s role in apoptosis and implications in disease processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ICAD Antibody (B-6) References:
- Functional differences of two forms of the inhibitor of caspase-activated DNase, ICAD-L, and ICAD-S. | Sakahira, H., et al. 1999. J Biol Chem. 274: 15740-4. PMID: 10336474
- DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. | Thomas, DA., et al. 2000. Immunity. 12: 621-32. PMID: 10894162
- Expression of ICAD-l and ICAD-S in human brain tumor and its cleavage upon activation of apoptosis by anti-Fas antibody. | Masuoka, J., et al. 2001. Jpn J Cancer Res. 92: 806-12. PMID: 11473733
- Growth phase-dependent expression of ICAD-L/DFF45 modulates the pattern of apoptosis in human colonic cancer cells. | Charrier, L., et al. 2002. Cancer Res. 62: 2169-74. PMID: 11929840
- DFF45/ICAD restores cisplatin-induced nuclear fragmentation but not DNA cleavage in DFF45-deficient neuroblastoma cells. | Takahashi, M., et al. 2007. Oncogene. 26: 5669-73. PMID: 17353905
- Caspase-2 cleaves DNA fragmentation factor (DFF45)/inhibitor of caspase-activated DNase (ICAD). | Dahal, GR., et al. 2007. Arch Biochem Biophys. 468: 134-9. PMID: 17945178
- Identification of ICAD-derived peptides capable of inhibiting caspase-activated DNase. | Kutscher, D., et al. 2012. FEBS J. 279: 2917-28. PMID: 22727028
- ICAD deficiency in human colon cancer and predisposition to colon tumorigenesis: linkage to apoptosis resistance and genomic instability. | Errami, Y., et al. 2013. PLoS One. 8: e57871. PMID: 23451280
- Minocycline inhibits ICAD degradation and the NF-κB activation induced by 6-OHDA in PC12 cells. | Jiang, BP., et al. 2014. Brain Res. 1586: 1-11. PMID: 25195972
- A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. | Enari, M., et al. 1998. Nature. 391: 43-50. PMID: 9422506
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ICAD Antibody (B-6) | sc-17818 | 200 µg/ml | $322.00 | |||
ICAD Antibody (B-6): m-IgG Fc BP-HRP Bundle | sc-536592 | 200 µg Ab; 10 µg BP | $361.00 | |||
ICAD Antibody (B-6): m-IgGκ BP-HRP Bundle | sc-533745 | 200 µg Ab; 40 µg BP | $361.00 | |||
ICAD Antibody (B-6): m-IgG2b BP-HRP Bundle | sc-549815 | 200 µg Ab; 10 µg BP | $361.00 |